The Chemistry Behind ADCs
Combining the selective targeting of tumor cells through antigen-directed recognition and potent cell-killing by cytotoxic payloads, antibody-drug conjugates (ADCs) have emerged in recent years as an efficient therapeutic approach for the treatment of various cancers. Besides a number of approved dr...
Main Authors: | Vesela Kostova, Patrice Désos, Jérôme-Benoît Starck, Andras Kotschy |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/5/442 |
Similar Items
-
Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody–Drug Conjugates for Cancer Therapy
by: Audrey Nathania Johan, et al.
Published: (2022-05-01) -
Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
by: Chi Hun Song, et al.
Published: (2023-11-01) -
Design and Validation of Linkers for Site-Specific Preparation of Antibody–Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site
by: Amit Kumar, et al.
Published: (2020-09-01) -
Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety
by: Yanming Wang, et al.
Published: (2020-03-01) -
Exploration of the antibody–drug conjugate clinical landscape
by: Heather Maecker, et al.
Published: (2023-12-01)